Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 9/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | RHOC | P08134 | 1/20 | 0.46 |
| ▸ | RHOA | P61586 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16210506 | 0.98 | LMNA (0.50) | LMNAMAPTHTTKDM4ESMN1; SMN2 | |
| SCHEMBL4905756 | 0.88 | LMNA (0.55) | LMNAMAPTHTTKDM4ESMN1; SMN2 | |
| SCHEMBL4903824 | 0.85 | LMNA (0.53) | LMNAMAPTHTTKDM4ESMN1; SMN2 | |
| SCHEMBL2056125 | 0.84 | TP53 (0.55) | LMNAMAPTHTTKDM4ESMN1; SMN2 | |
| SCHEMBL2236881 | 0.84 | GFER (0.66) | LMNAMAPTHTTKDM4ESMN1; SMN2 | |
| SCHEMBL4553327 | 0.84 | LMNA (0.51) | LMNAMAPTHTTKDM4ESMN1; SMN2 | |
| SCHEMBL2088799 | 0.84 | LMNA (0.54) | LMNAMAPTHTTKDM4ESMN1; SMN2 | |
| SCHEMBL12151145 | 0.84 | POLB (0.55) | LMNAMAPTHTTKDM4ESMN1; SMN2 | |
| SCHEMBL12151210 | 0.84 | LMNA (0.51) | LMNAMAPTHTTKDM4ESMN1; SMN2 | |
| SCHEMBL1715677 | 0.83 | IDO1 (0.51) | LMNAMAPTHTTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12313546-B2 | Sensing devices and chemosensors and compositions relating thereto | ROBERT BOSCH GMBH (DE) | 2025-05-27 | — | — | US | disclosed |
| US-20220034808-A1 | SENSING DEVICES AND CHEMOSENSORS AND COMPOSITIONS RELATING THERETO | ROBERT BOSCH GMBH (DE) | 2022-02-03 | — | — | US | disclosed |
| CN-113004267-A | Acceptor and spacer for fluorescence-based lead ion chemical sensors | 罗伯特·博世有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-2805718-B1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | EA PHARMA CO LTD (JP) | 2018-04-04 | — | — | EP | disclosed |
| WO-2018025872-A1 | LIQUID CRYSTAL DISPLAY ELEMENT EQUIPPED WITH LIQUID CRYSTAL PANEL HAVING CURVED SURFACE AND LIQUID CRYSTAL ALIGNING AGENT FOR SAME | 日産化学工業株式会社 | 2018-02-08 | — | — | WO | disclosed |
| US-9562043-B2 | Heterocyclic amide derivative and pharmaceutical product containing same | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | disclosed |
| US-9562043-B2 | Heterocyclic amide derivative and pharmaceutical product containing same | EA PHARMA CO., LTD. (JP) | 2017-02-07 | — | — | US | disclosed |
| EP-2805718-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | Ajinomoto Co., Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2012014898-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | 日産化学工業株式会社 (JP) | 2012-02-02 | — | — | WO | disclosed |
| WO-2010100606-A1 | NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | LMNA 2176/4885MAPT 65/4885HTT 1177/4885 |
| US-20140329796-A1 | HETEROCYCLIC AMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | TRPA1, TRPV1, TRPV2 | LMNA 3279/4885MAPT 1109/4885HTT 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.